{"id":"eca3358c-567c-4a3c-b488-541a3747647c","modelId":"e6527aa8-0ffa-42a7-9edb-837f1575ad96","versionId":null,"locationId":"6753d6b9-d63f-41f8-b672-4d80bdb4dd82","operatorId":null,"ownerId":null,"slug":"vicarious-v1-global","status":"operational","firstSeen":null,"manufacturerSerial":null,"reviewStatus":"reviewed","sources":[{"url":"https://rover.report","title":"Rover registry backfill","date_accessed":"2026-06-07"}],"notes":"Aggregate global deployment. V1 operations.","keyFacts":[],"reviewNote":null,"exposureHours":null,"exposureBasis":null,"customerSegment":null,"scaleTier":null,"contractValueUsd":null,"contractValueBasis":null,"customerCompanyId":null,"customerExternalName":null,"createdAt":"2026-06-08T01:08:26.512Z","updatedAt":"2026-06-08T01:08:26.512Z","model":{"id":"e6527aa8-0ffa-42a7-9edb-837f1575ad96","companyId":"9dc45318-fb87-4997-a06d-0b54567c6855","modelName":"V1","slug":"vicarious-v1","description":"Vicarious Surgical (based in the Waltham, Massachusetts area; public via a 2021 SPAC merger as NYSE: RBOT) is developing the V1, a single-port surgical robot concept built around a 9-degree-of-freedom human-like instrument and an immersive virtual-reality-style surgeon interface meant to transport the surgeon inside the patient. The headline finding is the company's distress: its first-quarter 2026 Form 10-Q carries an explicit going-concern substantial-doubt, with cash and short-term investments of $3.682 million as of March 31, 2026 and a stated runway only through the second quarter of 2026, a quarterly net loss of $7.329 million, and zero revenue ever, since the product has never been commercialized; NYSE trading was suspended on March 3, 2026 with delisting proceedings commenced, and the stock moved to the OTCQB on March 24, 2026 after a reverse split used as a survival maneuver. The registry records V1 at research maturity, because it has no FDA clearance and not even an FDA submission yet, with its planned De Novo pathway and first-in-human study repeatedly delayed, so under the verified-vs-claimed framework no clearance means research-tier regardless of years of demonstrations, and the differentiators remain engineering concepts in animal-lab and design-freeze stage. The lifecycle is recorded as active but materially at risk of becoming discontinued within the cash-runway window, and this record should be re-verified within weeks given the Q2-2026 cliff.","formFactor":"surgical","maturityStage":"research","lifecycleState":"active","supersededByModelId":null,"specs":{"notes":[{"label":"Verified","value":"Vicarious Surgical (Waltham MA area; went public via SPAC 2021, NYSE: RBOT) is developing the V1 single-port robot. The differentiators (9-DoF human-like instrument, immersive interface) are engineering concepts in animal-lab / design-freeze stage."},{"label":"Current status: DISTRESSED (the headline)","value":"Q1 2026 10-Q carries an EXPLICIT going-concern substantial-doubt. Cash + short-term investments = $3.682M (3/31/2026); runway only through Q2 2026. Q1 2026 net loss $7.329M; ZERO revenue ever (never commercialized). NYSE trading suspended Mar 3 2026, delisting commenced; moved to OTCQB Mar 24 2026. A reverse split was used as a survival maneuver."},{"label":"Maturity = research (gating not even submitted)","value":"NO FDA clearance and NO FDA submission yet (planned De Novo, first-in-human repeatedly delayed). V1 does nothing commercial: no revenue, no installed base, no cleared device. NO clearance = research-tier. At material risk of becoming discontinued within the runway window. RE-VERIFY within weeks given the Q2-2026 cash cliff."},{"label":"Claimed but NOT verified","value":"Any completed first-in-human procedure; a firm/met FDA submission date; that the company remains a going concern past Q2 2026; successful Nasdaq relisting; AI-assist or autonomy (none cleared or commercial; teleoperated by design)."},{"label":"Re-verify 2026-06-03","value":"Distress intact (Q1 2026 10-Q, filed Apr 30 2026: cash + ST investments $3.682M at 3/31/2026, runway through Q2 2026, Q1 net loss $7.329M, accumulated deficit $253.446M, still zero revenue, still NO FDA submission / NO first-in-human). NEW defensive action: applied to UPLIST to the Nasdaq Capital Market + filed a preliminary proxy for a board-authorized reverse stock split (ratio TBD) - both INTENTIONS/applications, NOT completed (does not yet meet Nasdaq initial-listing requirements). No bankruptcy, acquisition, or new financing closed. No lifecycle change; maturity stays research."}],"products":"V1: single-port system with a '9-DoF human-like' instrument and an immersive VR-style surgeon interface ('transport the surgeon inside the patient'). Pre-commercial; no FDA submission yet.","formFactor":"surgical (single-port surgical robot concept: 9-DoF human-like instrument + immersive VR-style surgeon interface)"},"manufacturerSerial":null,"reviewStatus":"reviewed","sources":[{"url":"https://www.businesswire.com/news/home/20260303-vicarious-surgical-nyse-delisting","title":"Vicarious Surgical receives NYSE delisting notice (Mar 3 2026)","sourceName":"Vicarious Surgical (Business Wire)"},{"url":"https://www.therobotreport.com/vicarious-surgical-faces-nyse-delisting-again/","title":"Vicarious Surgical faces NYSE delisting; moved to OTCQB","sourceName":"The Robot Report"},{"url":"https://www.massdevice.com/vicarious-surgical-timeline-delay/","title":"Vicarious Surgical moves its surgical-robot timeline back again","sourceName":"MassDevice"},{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=RBOT","title":"Vicarious Surgical Q1 2026 10-Q (going-concern; $3.682M cash; runway thru Q2 2026)","sourceName":"SEC EDGAR"},{"url":"https://www.sec.gov/Archives/edgar/data/0001812173/000121390026049749/ea0287711-10q_vicarious.htm","title":"Vicarious Surgical Form 10-Q Q1 FY2026 (filed Apr 30 2026): cash + ST investments $3.682M, runway through Q2 2026, accumulated deficit $253.446M, zero revenue","sourceName":"SEC EDGAR"},{"url":"https://www.businesswire.com/news/home/20260316676583/en/Vicarious-Surgical-Announces-Strategic-Plan-to-Pursue-Nasdaq-Listing","title":"Vicarious Surgical announces strategic plan to pursue Nasdaq listing (application + reverse-split proxy; not yet completed)","sourceName":"Business Wire"}],"aliases":["Vicarious V1","Vicarious Surgical System"],"collisionRisk":"low","reviewNote":null,"manufacturerTermForTeleop":null,"createdAt":"2026-06-03T20:12:38.213Z","updatedAt":"2026-06-04T02:39:56.366Z","company":{"id":"9dc45318-fb87-4997-a06d-0b54567c6855","name":"Vicarious Surgical","slug":"vicarious-surgical","description":"US surgical-robotics startup (Waltham MA; SPAC-listed 2021, RBOT) developing the V1 single-port robot; pre-commercial and financially distressed (going-concern; NYSE-delisted Mar 2026, now OTCQB).","status":"distressed (going-concern; NYSE-delisted Mar 2026; OTCQB: RBOT)","founded":2014,"hq":"Waltham, Massachusetts, USA","fundingTotal":null,"type":"both","reviewStatus":"reviewed","sources":[{"url":"https://www.businesswire.com/news/home/20260303-vicarious-surgical-nyse-delisting","title":"Vicarious Surgical receives NYSE delisting notice (Mar 3 2026)","sourceName":"Vicarious Surgical (Business Wire)"},{"url":"https://www.therobotreport.com/vicarious-surgical-faces-nyse-delisting-again/","title":"Vicarious Surgical faces NYSE delisting; moved to OTCQB","sourceName":"The Robot Report"},{"url":"https://www.massdevice.com/vicarious-surgical-timeline-delay/","title":"Vicarious Surgical moves its surgical-robot timeline back again","sourceName":"MassDevice"}],"keyFacts":[{"label":"Product","value":"V1 single-port robot (9-DoF instrument + VR interface); pre-commercial, no FDA submission."},{"label":"Status","value":"Going-concern; cash thru Q2 2026; NYSE-delisted Mar 2026. RE-VERIFY soon."}],"aliases":["Vicarious","RBOT"],"collisionRisk":"low","reviewNote":null,"createdAt":"2026-06-03T20:12:37.271Z","updatedAt":"2026-06-03T20:12:37.271Z"}},"version":null,"location":{"id":"6753d6b9-d63f-41f8-b672-4d80bdb4dd82","name":"Global","slug":"global","kind":"city","parentLocationId":null,"region":null,"lat":null,"lng":null,"reviewStatus":"unreviewed","aliases":[],"collisionRisk":"high","reviewNote":null,"createdAt":"2026-06-08T01:03:25.017Z","updatedAt":"2026-06-08T01:03:25.017Z"},"operator":null,"owner":null,"derived":{"trustTier":"unverified","currentPosture":null},"jsonLd":{"@context":"https://schema.org","@type":"Event","@id":"https://registry.deploy.report/deployments/vicarious-v1-global","url":"https://registry.deploy.report/deployments/vicarious-v1-global","name":"V1 at Global","identifier":"eca3358c-567c-4a3c-b488-541a3747647c","location":{"@type":"Place","@id":"https://registry.deploy.report/locations/global","name":"Global"},"organizer":{"@type":"Organization","@id":"https://registry.deploy.report/companies/vicarious-surgical","name":"Vicarious Surgical"},"about":{"@type":"Product","@id":"https://registry.deploy.report/models/vicarious-v1","name":"V1"},"publisher":{"@id":"https://deploy.report/#organization"}},"framework_metadata":{"framework_schema_version":"0.1.0","verification_status":"verified","maturity_stage":"research","lifecycle_state":"active","architectural_position":{"cohort":"surgical","sub_cohorts":[]},"within_cohort_verified_vs_claimed_pair":null,"cap_flags":[],"verification_depth":{"sources_count":1,"primary_source_types":[]}}}